MCID: MCN001
MIFTS: 52

Mucinous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 12 15 73
Mucin-Producing Adenocarcinoma 12 73
Pseudomyxoma Peritonei with Unknown Primary Site 12
Mucin-Secreting Adenocarcinoma 12
Mucin-Secreting Carcinoma 12
Adenocarcinoma, Mucinous 44
Mucous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3030
MeSH 44 D002288
SNOMED-CT 68 72495009 900006

Summaries for Mucinous Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to endometrial mucinous adenocarcinoma and appendix adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Pathways in cancer and Development EGFR signaling pathway. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, prostate and appendix, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 endometrial mucinous adenocarcinoma 34.0 CDKN2A MUC1
2 appendix adenocarcinoma 33.6 CDX2 KRT20 KRT7
3 ovarian mucinous adenocarcinoma 33.4 CDX2 KRT20 KRT7 MUC2
4 pseudomyxoma peritonei 31.3 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
5 teratoma 30.9 CDX2 KRT7 NKX2-1
6 krukenberg carcinoma 30.8 KRT20 KRT7
7 ovarian germ cell teratoma 30.8 KRT7 NKX2-1
8 transverse colon cancer 30.6 KRT20 KRT7
9 ovarian large-cell neuroendocrine carcinoma 30.6 KRT20 KRT7
10 sertoli-leydig cell tumor 30.6 KRT7 MUC1
11 nephrogenic adenoma 30.6 KRT7 MUC1
12 cystadenocarcinoma 30.6 KRT7 MUC1 MUC2
13 thymus adenocarcinoma 30.6 CDX2 KRT20 KRT7
14 rectum adenocarcinoma 30.3 CDX2 KRT20 KRT7
15 dermoid cyst 30.1 KRT20 KRT7 MUC1
16 villous adenoma 30.0 CDX2 KRAS KRT20 MUC1
17 gallbladder cancer 29.9 KRAS MLH1 MUC2
18 microinvasive gastric cancer 29.9 CDX2 MLH1 MUC2
19 colon adenocarcinoma 29.8 KRAS KRT20 MLH1
20 vulva adenocarcinoma 29.7 CDKN2A CDX2 KRT20 KRT7
21 cystadenoma 29.6 KRT20 KRT7 MUC1 MUC2
22 cystic teratoma 29.6 CDX2 KRT20 KRT7 MUC2 NKX2-1
23 adenoid cystic carcinoma 29.6 KRAS KRT20 KRT7 MUC1
24 endocervical adenocarcinoma 29.2 CDKN2A CDX2 KRT20 KRT7
25 adenocarcinoma in situ 29.1 CDKN2A CDX2 KRAS KRT20 KRT7
26 large cell neuroendocrine carcinoma 28.9 EGFR KRT20 KRT7 NKX2-1
27 peritoneal mesothelioma 28.9 CDKN2A EGFR MUC1
28 mucoepidermoid carcinoma 28.8 EGFR KRT7 MUC1 MUC2
29 gastrointestinal stromal tumor 28.7 CDKN2A EGFR KRAS
30 thymus cancer 28.6 EGFR KRT7 MUC1 NKX2-1
31 adenocarcinoma 28.6 ALK CDKN2A EGFR KRAS MLH1 MUC1
32 appendix cancer 28.6 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
33 transitional cell carcinoma 28.3 CDKN2A EGFR KRT20 KRT7
34 small intestinal adenocarcinoma 28.2 CDX2 EGFR KRAS MUC1 MUC2
35 horseshoe kidney 28.0 CDX2 EGFR KRT20 KRT7 NKX2-1
36 renal cell carcinoma, nonpapillary 27.9 EGFR KRT20 KRT7 MUC1 NKX2-1
37 pancreas adenocarcinoma 27.9 CDKN2A EGFR KRAS MUC1 MUC2
38 endometrial cancer 27.8 CDKN2A EGFR KRAS KRT7 MLH1
39 gastric cancer 27.3 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
40 colorectal adenocarcinoma 26.9 CDX2 EGFR KRAS KRT20 KRT7 MLH1
41 ovarian cancer 26.8 EGFR KRAS KRT7 MLH1 MUC1 MUC2
42 colorectal cancer 25.9 CDKN2A CDX2 EGFR KRAS KRT20 MLH1
43 lung cancer susceptibility 3 25.1 ALK CDKN2A CDX2 EGFR KRAS KRT20
44 colon mucinous adenocarcinoma 12.2
45 mucinous adenocarcinoma of ovary 12.2
46 mucinous adenocarcinoma of the appendix 12.1
47 cervical mucinous adenocarcinoma 12.0
48 ampulla of vater mucinous adenocarcinoma 12.0
49 bile duct mucinous adenocarcinoma 12.0
50 uterine ligament mucinous adenocarcinoma 12.0

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.81 EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 9.81 KRAS
3 Decreased viability GR00221-A-1 9.81 EGFR KRAS ALK CDKN2A
4 Decreased viability GR00221-A-2 9.81 KRAS
5 Decreased viability GR00221-A-3 9.81 CDKN2A
6 Decreased viability GR00221-A-4 9.81 CDKN2A EGFR ALK
7 Decreased viability GR00301-A 9.81 KRAS
8 Decreased viability GR00381-A-1 9.81 KRAS
9 Decreased viability GR00402-S-2 9.81 EGFR KRAS ALK CDKN2A MUC1
10 Decreased cell migration GR00055-A-1 9.26 EGFR KRAS ALK MUC1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 NKX2-1 EGFR KRAS KRT7 CDKN2A MLH1
2 endocrine/exocrine gland MP:0005379 9.97 NKX2-1 ALK KRAS CDKN2A MLH1 CDX2
3 homeostasis/metabolism MP:0005376 9.97 EGFR NKX2-1 ALK KRAS KRT7 CDKN2A
4 digestive/alimentary MP:0005381 9.95 KRAS CDKN2A MLH1 CDX2 MUC2 EGFR
5 neoplasm MP:0002006 9.86 KRAS ALK CDKN2A MLH1 CDX2 MUC2
6 reproductive system MP:0005389 9.5 EGFR NKX2-1 ALK KRAS CDKN2A MLH1
7 pigmentation MP:0001186 9.46 EGFR ALK KRAS CDKN2A
8 respiratory system MP:0005388 9.1 EGFR NKX2-1 ALK KRAS CDKN2A MLH1

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
8
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
12
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
13
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
14
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
17
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
18
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
19
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
20
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
21
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
22
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
23
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
24
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
25
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
28
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
30
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
32
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
33
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
34 Alkylating Agents Phase 3,Phase 2,Phase 1
35 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
36 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antidotes Phase 3,Phase 2,Phase 1
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
43 Calcium, Dietary Phase 3,Phase 2,Phase 1
44 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
45 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Mitomycins Phase 3
47 Nucleic Acid Synthesis Inhibitors Phase 3
48 Protective Agents Phase 3,Phase 2,Phase 1
49 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
4 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
8 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
9 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
10 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
11 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
12 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
13 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
14 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
16 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
17 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
18 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
19 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
20 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
21 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
22 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
23 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
24 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
25 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
26 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
27 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
28 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3 capecitabine;fluorouracil;leucovorin calcium;irinotecan hydrochloride;oxaliplatin
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
34 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
35 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
36 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
37 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
38 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
39 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
40 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
41 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
42 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
43 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
44 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
45 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
46 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
47 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
48 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
49 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
50 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

41
Colon, Prostate, Appendix, Lung, Ovary, Liver, Pancreas

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 593)
# Title Authors Year
1
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
2
Mucinous Adenocarcinoma of the Scalp: Primary Cutaneous Neoplasm Versus Underlying Metastatic Disease. ( 29876191 )
2018
3
Right-colon mucinous adenocarcinoma mimicking a hydatid cyst. ( 29313694 )
2018
4
GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4I+ expression, and KRAS mutations. ( 29469192 )
2018
5
Multicystic mucinous adenocarcinoma of the uterine cervix compared with benign multicystic lesions: Multiparametric MR features. ( 29624774 )
2018
6
Case of mucinous adenocarcinoma of the lung associated with congenital pulmonary airway malformation in a neonate. ( 29441110 )
2018
7
Primary Mucinous Adenocarcinoma of Skin: Myoepithelial Cells are a Clue to its Diagnosis. ( 29692460 )
2018
8
Duodenal mucinous adenocarcinoma presenting as ileus, obstructive jaundice and massive ascites: A case report. ( 29456851 )
2018
9
Mucinous adenocarcinoma arising from chronic perianal fistula mimicking horseshoe abscess. ( 29622704 )
2018
10
Laparoscopic abdominoperineal resection for the treatment of a mucinous adenocarcinoma associated with an anal fistula. ( 29593864 )
2018
11
Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung. ( 29538611 )
2018
12
Pseudomyxoma Peritonei Arising From Urachal Mucinous Adenocarcinoma. ( 29024737 )
2018
13
Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. ( 29515761 )
2018
14
Perianal Mucinous Adenocarcinoma Diagnosed by Histological Study of Anorectal Abscess with Fistula. ( 29577055 )
2018
15
Perianal Paget disease secondary to pagetoid spread of mucinous adenocarcinoma of the anal canal. ( 29400297 )
2018
16
Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. ( 29375717 )
2018
17
Rare Case of Iliopsoas Abscess Secondary to Mucinous Adenocarcinoma of the Colon: A Case Report. ( 29854689 )
2018
18
FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. ( 29267283 )
2017
19
Mucinous adenocarcinoma and non-mucinous adenocarcinoma: differing clinicopathological characteristics and computed tomography features in gastric cancer. ( 28501848 )
2017
20
Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells. ( 29138597 )
2017
21
Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a newborn with antenatal diagnosis of congenital pulmonary airway malformation. ( 28889407 )
2017
22
Mucinous adenocarcinoma arising in an end ileostomy - a video vignette. ( 28677338 )
2017
23
Primary Mucinous Adenocarcinoma of the Thymus: A Case Report and Literature Review. ( 28956749 )
2017
24
Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. ( 29124485 )
2017
25
Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )
2017
26
Primary mucinous adenocarcinoma of the vulva, intestinal type. ( 28791269 )
2017
27
Fluorodeoxyglucose-avid pulmonary mucinous adenocarcinoma presenting with nonfluorodeoxyglucose-avid cystic brain lesions of unknown etiopathology: Brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography-computed tomography imaging features and additional value of whole-body positron emission tomography acquisition. ( 29199669 )
2017
28
Cystic metastasis from a mucinous adenocarcinoma of duodenum mimicking type II choledochal cyst: A case report. ( 29290919 )
2017
29
The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. ( 28060142 )
2017
30
Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )
2017
31
Mucinous adenocarcinoma of unknown primary presenting with dysphagia. ( 29223385 )
2017
32
Mucinous adenocarcinoma in association with hidradenitis suppurativa. ( 28597923 )
2017
33
Pulmonary Invasive Mucinous Adenocarcinoma and Mixed Invasive Mucinous/Non-Mucinous Adenocarcinoma- A Clinicopathological and Molecular Genetic Study with Survival Analysis. ( 28823574 )
2017
34
Giant mucinous adenocarcinoma of the appendix: a case report. ( 28756772 )
2017
35
Molecular characteristics of multifocal invasive mucinous adenocarcinoma of the lung: Report of a rare case. ( 28851076 )
2017
36
Mucinous adenocarcinoma in association with hidradenitis suppurativa: a new example of isoscartopic response. ( 29271499 )
2017
37
Sonographic image of cervix epithelioid trophoblastic tumor coexisting with mucinous adenocarcinoma in a postmenopausal woman: A case report. ( 28930821 )
2017
38
Sertoli-Leydig cell tumor of the ovary masquerading as a mucinous adenocarcinoma: a frozen section pitfall. ( 29081925 )
2017
39
Agenesis of the dorsal pancreas associated with mucinous adenocarcinoma and cystic teratoma: a case report and literature review. ( 28174646 )
2017
40
Synchronous mucinous adenocarcinoma of the recto sigmoid revealed by and seeding an anal fistula. (A case report and review of the literature). ( 28641190 )
2017
41
Biology of invasive mucinous adenocarcinoma of the lung. ( 29114467 )
2017
42
Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report. ( 28687977 )
2017
43
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. ( 27744658 )
2017
44
Mucinous adenocarcinoma on perianal fistula. A rising entity? ( 28929316 )
2017
45
Urachal mucinous adenocarcinoma with pseudomyxoma peritonei: A case report. ( 28858081 )
2017
46
Vulvar Carcinosarcoma Composed of Intestinal-type Mucinous Adenocarcinoma Associated With Anaplastic Pleomorphic and Spindle Cell Carcinoma and Heterologous Chondrosarcomatous and Osteosarcomatous Elements: A Case Report and Review of the Literature. ( 28319579 )
2017
47
Presentation of mucinous adenocarcinoma of renal pelvis masquerading as gross hydronephrosis: A histopathological surprise. ( 28702413 )
2017
48
KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. ( 28932588 )
2017
49
Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study. ( 28785968 )
2017
50
Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )
2017

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1 12.38 ALK CDKN2A EGFR KRAS MLH1
2
Show member pathways
12.15 EGFR KRAS MUC1 NRG1
3
Show member pathways
12.02 ALK CDKN2A EGFR KRAS NRG1
4 11.89 EGFR KRAS MLH1
5 11.82 ALK EGFR NRG1
6
Show member pathways
11.77 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
7
Show member pathways
11.75 EGFR KRAS NRG1
8 11.65 CDKN2A EGFR KRAS
9
Show member pathways
11.61 EGFR KRAS NRG1
10 11.36 CDKN2A EGFR KRAS
11 11.08 EGFR KRAS NRG1
12 10.96 EGFR KRAS
13
Show member pathways
10.93 EGFR KRAS

GO Terms for Mucinous Adenocarcinoma

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.67 CDKN2A KRAS NKX2-1 NRG1
2 peptidyl-tyrosine phosphorylation GO:0018108 9.61 ALK EGFR NRG1
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.43 KRAS MUC1 MUC2
4 positive regulation of cellular senescence GO:2000774 9.4 CDKN2A KRAS
5 epithelial tube branching involved in lung morphogenesis GO:0060441 9.32 KRAS NKX2-1
6 negative regulation of ERBB signaling pathway GO:1901185 9.16 EGFR NRG1
7 cerebral cortex cell migration GO:0021795 8.96 EGFR NKX2-1
8 ERBB2 signaling pathway GO:0038128 8.8 EGFR KRAS NRG1

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.8 ALK EGFR NRG1

Sources for Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....